PDCD1 and neoplasm: Monoclonal antibodies which block immune checkpoints expressed on T cells, such as PD-1 and CTLA-4, or tumour cells, such as programmed death ligand 1 (PD-L1), have demonstrated effectiveness across a wide range of solid tumours (204).